证券之星app
广告
首页 > 股票 > 研报 > 研报指标速递
序号证券代码证券简称研究机构最新评级目标价报告日收盘价预期涨幅盈利预测报告日期报告摘要
26年EPS27年EPS28年EPS
1601318中国平安招银国际买入73.0051.7641%6.988.349.062026-10-23报告摘要

3Q26 preview: NPAT to hit quarterly trough while OPAT remained robust

中国平安(601318)
    Ping An is scheduled to report3Q26quarterly earnings on28Oct(Wed)post-market.We expect Group OPAT to grow8.1%YoY in9M26(1H26:+8.3%),implying broadlyintact3Q growth of7.6%YoY(vs1Q/2Q26:+7.6%/+9.0%)unaffected by the quarterlycapital market volatilities.Group NPAT could drop29%YoY in9M26per our estimate(vs.1H26:+36%),dragged by sharp A-share market corrections as CSI300/SHCOMPindex was down13%/6%in3Q26(vs.3Q25:+18%/+13%).NAV could rise3.0%fromyear-start,flat QoQ,as a combined result of1)higher fair value gains from OCI equitiesi.e.the CSI Dividend/CSI High Dividend Low Vol index rose9%/10%in3Q26and PingAn’s higher-than-most-peers OCI stock exposure(1H26:66%);2)China’s10yr govt.bond yield trending lower in3Q,which could boost OCI bonds’fair value,offset by the3)increase in liability reserve charge.NBV could see a double-digit decline,which weestimate to fall14%YoY in9M26.This was weighed by an industry-wide salesslowdown and a one-off negative impact on margin given the high comparative set priorto actuarial assumption changes by end-FY25.Despite an anticipated recovery in4Q,we revise down our full-year NBV growth forecast to bake in the3Q26lag.P&Ccombined ratio could be better than expected and we forecast to improve0.5pct YoYto96.5%in9M26.Maintain BUY with our H/A-share price target unchanged atHK$81/RMB73.
    3Q NPAT to hit a quarterly trough within the year while OPAT stayed robust.We expect Group NPAT to decline29%YoY in9M26,mainly weighed by A-sharemarket headwinds in3Q26(CSI300/SHCOMP:-13%/-6%,vs.3Q25:+18%/+13%),offsetting1H investment gains.Despite this softness,Ping An couldoutperform peers in3Q IFRS net earnings given its greater exposure to OCI stocksthan peers(1H26:66%in stock mix/9.6%of insurance funds vs.peers’average of40%/4.7%).Group OPAT could grow8.1%YoY in9M26,translating into a7.6%YoY lift in3Q,of which we expect the L&H,PAB,and AM segments to remain soliddrivers.
    NBV to fall on premium slowdown and a margin high-base.We forecast NBVto decline14%YoY in9M26(vs.1H26:+11%),dragged by an industry-wide salesslowdown against a strong comparative prior to the PIR cuts in Sep2025,the feed-through impact of tighter bancassurance regulation,and a one-off negative marginimpact given the base set before the actuarial assumption changes by end-2025.4Q NBV recovery could come along with the ramp-up of the2027jumpstart sales,yet the agency force would still need more time shifting towards life products withextended payment terms.We revise down our FY26E NBV growth forecast to4%.
    P&C COR likely better than previous estimates.We estimate P&C combinedratio to improve0.5pct YoY to96.5%in9M26despite under the backdrop ofincreasing natural catastrophe(NAT CAT)claims in3Q.The COR improvementcould be a result of1)ongoing tightening of expense control,allowing the decreaseof expense ratio more than offset the increase in claims ratio(CMBI est);2)robustunderwriting prints in1H26left space for claims on major catastrophes in3Q26.On the premiums front,we maintain our forecast on low single-digit growth in9M.
    TP unchanged; yield topped among peers. The stock is trading at 0.47x FY26EP/EV and 0.7x FY26E P/B with an avg. 3yr forward ROE >13% and a yield closeto 7% amid recent share price corrections, standing as the highest among peers.We expect a clearer guidance on 4Q-to-date life sales momentum and updates forthe 2027 jumpstart sales during the call. Maintain BUY, with our H/A-share TPunchanged at HK$81/RMB73 which implies 0.8x FY26E P/EV and 1.2x FY26E P/B
    Key risks: 1) regulatory tightening on life insurance and financial conglomerates; 2)heightened equity market volatility; 3) a prolonged low-interest rate environment; 4)intensified pricing competition in P&C industry; 5) asset quality deterioration; and 6) asignificant decline in Group capital level weighing on DPS growth, etc.
    Company description: Founded in 1988, Ping An is a leading financial conglomeratewith businesses spanning life and P&C insurance, pension, banking, brokerage, trust,and other financial services. The company pursues a technology-empowered growthstrategy across core financial businesses of insurance, banking, brokerage, and assetmanagement. As of FY25, Ping An ranked as the second-largest Life and P&C insurerin China by total written premiums. The banking business segment is operated by itssubsidiary Ping An Bank (000001 CH, 58% Group stake), which has a focus on retailand SME businesses. Ping An Healthcare and Technology (1833 HK, 53% Groupstake) was listed in May 2018 as China’s first listed internet-health company.

上一页1下一页
网站导航 | 公司简介 | 法律声明 | 诚聘英才 | 征稿启事 | 联系我们 | 广告服务 | 举报专区
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年